Blog | BioInformant

ExCellThera Developing Cord Blood Expansion Technology ECT-001 for Multiple Myeloma

May 14, 2018 By Cade Hildreth, Founder & President Leave a Comment

ECT-001 is basis of new clinical trial for multiple myeloma

MONTREAL, May 14, 2018 – ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced today that its lead platform, ECT-001, will be used as part of a new Phase I/II clinical trial in patients with multiple myeloma. The study will enroll up to 20 high-risk, multiple myeloma patients from the Hôpital Maisonneuve-Rosemont in Montreal, Canada. [Read more…]

Hemostemix Announces First Patient Treated in Phase II Clinical Trial

May 3, 2018 By Cade Hildreth, Founder & President Leave a Comment

CALGARY, Alberta, May 03, 2018 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) announces that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”). The first patient was treated at the Vancouver Coastal Health Research Institute (“VCHRI”), a world leader in translational health research for new therapies, led by the principal investigator, Dr. York N. Hsiang, MB ChB MHSc FRCSC. [Read more…]

Who is Global Cord Blood Corporation (Previously China Cord Blood Corporation)?

May 3, 2018 By Cade Hildreth, Founder & President 1 Comment

Global Cord Blood Corporation (NYSE: CO), previously named China Cord Blood Corporation (CCBC), became the first cord blood bank in China when it began operations in 2003. It was the first cord blood bank in China to receive ISO900 certification and is AABB accredited. It is also the largest cord blood banking operator in China in terms of geographical coverage and the only bank operating with multiple licenses.

On February 7, 2018, the company’s Board of Directors announced that it was pursuing shareholder approval to change the Company’s name from “China Cord Blood Corporation” to “Global Cord Blood Corporation” (GCBC). The name change reflects the company’s growing interest in international expansion. [Read more…]

Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine

May 1, 2018 By Cade Hildreth, Founder & President Leave a Comment

Company is developing adult stem cell-based therapies for patients with incurable vascular conditions

INDIANAPOLIS, May 1, 2018 — Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. [Read more…]

Abeona Becomes First Company to Secure Two RMATs

April 27, 2018 By Cade Hildreth, Founder & President Leave a Comment

Abeona Therapeutics announced the U.S. FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, the company’s AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease.

It was the 16th RMAT designation awarded by the FDA and a landmark achievement in that it makes Abeona the first company to achieve two RMAT designations.

Headquartered in Dallas, TX, Abeona (NASDAQ: ABEO) is a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases. Abeona’s first RMAT designation was for its EB-101 gene therapy for Epidermolysis Bullosa in January 2018. [Read more…]